Kevin Chow has over two decades of experience leading business development, corporate strategy and operations in the biopharmaceutical industry. Dr. Chow is the co-founder, President & CEO of Mitera Biosciences, an autoimmune disease focused bioventure established in collaboration with Cedars Sinai (Los Angeles). He also serves as President of Incisive Genetics, focusing on non-viral delivery of CRISPR gene editing using lipid nanoparticles. Previously he was co-founder, President and CEO of Vitaeris (acquired by CSL Behring in June 2020), a biotechnology company conducting a multi-national Phase 3 study in kidney transplant rejection. Prior to co-founding Vitaeris in early 2016, Dr. Chow served as Head of Business Development at Alder Biopharmaceuticals, where he led partnering efforts for Alder’s monoclonal antibody pipeline. Previously, Dr. Chow led pulmonary in-licensing at Gilead Sciences and served as Director of Business Development for Corus Pharma, a specialty pharmaceutical company focused on cystic fibrosis and asthma drug development. From 2000-2003 Dr. Chow served in various business development roles with Diversa Corporation.Dr. Chow holds B.Sc., M.Sc., and Ph.D. degrees in Microbiology and Immunology from the University of British Columbia in Vancouver, Canada.